Literature DB >> 12095625

Inhibition of ubiquitin-dependent proteolysis by a synthetic glycine-alanine repeat peptide that mimics an inhibitory viral sequence.

Ainars Leonchiks1, Vaya Stavropoulou, Anatoly Sharipo, Maria G Masucci.   

Abstract

The glycine-alanine repeat (GAr) of the Epstein-Barr virus nuclear antigen-1 is a cis-acting transferable element that inhibits ubiquitin/proteasome-dependent proteolysis in vitro and in vivo. We have here examined the effect of a synthetic 20-mer GAr oligopeptide on the degradation of iodinated or biotin labeled lysozyme in a rabbit reticulocyte lysates in vitro assay. Micromolar concentrations of the GA-20 peptide inhibited the hydrolysis of lysozyme without significant effect on ubiquitination. Addition of the peptide did not inhibit the hydrolysis of fluorogenic substrate by purified proteasomes and did not affect the ubiquitination of lysozyme. An excess of the peptide failed to compete for binding of a synthetic tetra-ubiquitin complex to the S5a ubiquitin-binding subunit of the 19S regulator, confirming that the GAr does not block the access of ubiquitinated substrates to the proteasome. Our data suggest that the GAr may act by destabilizing the interaction of ubiquitinated substrates with the proteasome and promote the premature release of the substrate.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12095625     DOI: 10.1016/s0014-5793(02)02897-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  4 in total

Review 1.  Peptide-guided gene delivery.

Authors:  Molly E Martin; Kevin G Rice
Journal:  AAPS J       Date:  2007-02-09       Impact factor: 4.009

2.  Gly-Ala repeats induce position- and substrate-specific regulation of 26 S proteasome-dependent partial processing.

Authors:  Chrysoula Daskalogianni; Sébastien Apcher; Marco M Candeias; Nadia Naski; Fabien Calvo; Robin Fåhraeus
Journal:  J Biol Chem       Date:  2008-08-29       Impact factor: 5.157

3.  Effects of APC De-targeting and GAr modification on the duration of luciferase expression from plasmid DNA delivered to skeletal muscle.

Authors:  Maria C Subang; Rewas Fatah; Ying Wu; Drew Hannaman; Jason Rice; Claire F Evans; Yuti Chernajovsky; David Gould
Journal:  Curr Gene Ther       Date:  2015       Impact factor: 4.391

Review 4.  Engineered biological entities for drug delivery and gene therapy protein nanoparticles.

Authors:  Joan Domingo-Espín; Ugutz Unzueta; Paolo Saccardo; Escarlata Rodríguez-Carmona; José Luís Corchero; Esther Vázquez; Neus Ferrer-Miralles
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.